Vamikibart for Diabetic Macular Edema

Vamikibart for Diabetic Macular Edema
82%63%43%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12Apr 26 • YES 52.0%Apr 27 • YES 62.0%Apr 28 • YES 62.2%Apr 29 • YES 75.7%Apr 30 • YES 75.7%May 1 • YES 75.7%May 2 • YES 75.7%May 3 • YES 75.7%May 4 • YES 76.0%May 5 • YES 76.0%May 7 • YES 49.5%May 11 • YES 49.5%May 12 • YES 49.5%
Hoffmann-La Roche ($RHHBY)
No stock closeNo stock close$51.85$50.96$50.06Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12Apr 27 • RHHBY $51.22Apr 28 • RHHBY $51.04Apr 29 • RHHBY $50.43Apr 30 • RHHBY $50.88May 1 • RHHBY $51.00May 4 • RHHBY $50.28May 5 • RHHBY $50.84May 6 • RHHBY $51.63May 7 • RHHBY $50.59May 8 • RHHBY $51.09May 11 • RHHBY $51.41May 12 • RHHBY $51.18

Will this trial show a positive result on mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve Participants, Baseline, Week 44 and Week 48?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
No oracle findings have been stored for this trial yet.
Stats
Latest Run
No runs yet
Model
No runs yet
Runs
0 runs